Chemotherapy‑Based Immunomodulators for Crohn’s Disease: Methotrexate & Mercaptopurine Overview

Certain chemotherapy agents, notably methotrexate and mercaptopurine (6‑MP), are proven immunomodulators for Crohn’s disease. By tempering the immune response, they reduce intestinal inflammation and can help patients taper off steroids while maintaining remission.

Although chemotherapy is best known for cancer treatment, low‑dose regimens of these drugs have been safely repurposed for autoimmune conditions. Regular monitoring by a gastroenterologist ensures efficacy and minimizes risks.

Methotrexate

Originally developed for breast cancer and later for lymphoma and leukemia, methotrexate is administered at a much lower dose for Crohn’s disease—typically once weekly by subcutaneous injection. Its anti‑inflammatory effect stems from inhibition of rapidly dividing cells, which curtails the immune cascade that drives gut inflammation.

Monitoring & safety: Patients usually undergo blood work every 8 weeks to assess liver and kidney function and to track complete blood counts. Because methotrexate can depress bone‑marrow production, clinicians watch for anemia, neutropenia, or thrombocytopenia. Pulmonary toxicity, though rare, is monitored by asking about persistent cough or shortness of breath.

Common side effects include headache, nausea, vomiting, and fatigue. To offset folate depletion, a daily folic acid supplement is recommended.

Contraindications: Methotrexate is absolutely contraindicated in pregnancy due to teratogenic risk and potential fetal loss.

Mercaptopurine (6‑MP)

Mercaptopurine, an antimetabolite, is taken orally in tablet form. It interferes with nucleic‑acid synthesis, thereby dampening the overactive immune response characteristic of Crohn’s disease.

Potential adverse effects are more pronounced than with methotrexate and may include temporary reductions in white‑ and red‑blood‑cell counts, raising infection and anemia risks. Hepatotoxicity and pancreatitis have also been reported, alongside classic chemotherapy symptoms such as nausea and vomiting.

Because of these risks, patients on 6‑MP require regular complete‑blood‑count and liver‑function testing, typically every 2–3 months, with dose adjustments made as needed.